Xilio Therapeutics Q3 2022 net loss $19.8M; XTX202 reaches target dose; XTX301 IND cleared

Xilio Therapeutics, Inc.

2022-Q3 EPS reported -$2.40

Cash $139.1M as of Sep 30, 2022; runway into Q2 2024.
Net loss $19.8M in Q3 2022 vs $16.3M in Q3 2021; R&D expense $13.0M.
XTX202 (IL-2) dosed at target 1 mg/kg; no vascular leak syndrome; CD8+ T cell increases seen.
FDA cleared IND for XTX301 (IL-12); Phase 1 start expected Q1 2023.
Company will seek partner for XTX101 (anti-CTLA-4); will not initiate a Phase 2 alone.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Xilio Therapeutics, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2022

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Xilio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-017015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.